"A clinical trial to access the safety and efficacy of intratumoral injections of ErbB2-CAR expressing NK-92 cells in relapsed glioblastoma."
Colloquium in Pathophysiology, Infectiology and Immunology by Torsten Tonn, MD (Transfusion Medicine, TU Dresden Germany)
Torsten Tonn, holds the chair for Transfusion Medicine at the Medical Faculty Carl Gustav Carus, Technical University Dresden (Germany) and is medical director (CEO) of the German Red Cross Blood Donation Service North/East. Prior to this, Torsten Tonn worked 15 years at the department for Transfusion Medicine, University Hospital Frankfurt/M, where he was head of the apheresis and cell & gene therapy unit. His scientific focus has been to facilitate the transfer of cell based therapies into clinical applications. He pioneered first in human clinical trials using the off-the-shelf NK cell line NK-92 and together with Winfried Wels (Frankfurt/Germany) engineered it to express tumour specific chimeric antigen receptors (CARs). Moreover he translated streptamer-based cell isolation processes for antigen specific donor T lymphocytes into clinical practice. Torsten Tonn served in many committees, among them the cell based product working party (CPWP) of the CAT (European Medicines Agency, EMA).